Showing 301 - 320 results of 6,670 for search '(( significant amount decrease ) OR ( significant ((step decrease) OR (we decrease)) ))', query time: 0.50s Refine Results
  1. 301
  2. 302
  3. 303
  4. 304
  5. 305
  6. 306
  7. 307
  8. 308
  9. 309

    The RehaGait® system. by Johanna Rydja (12300797)

    Published 2025
    “…Step height was normalized postoperatively; all other variables remained significantly worse than the HI. …”
  10. 310

    Flow chart of included patients and dropouts. by Johanna Rydja (12300797)

    Published 2025
    “…Step height was normalized postoperatively; all other variables remained significantly worse than the HI. …”
  11. 311

    Dataset of the analyzed data. by Johanna Rydja (12300797)

    Published 2025
    “…Step height was normalized postoperatively; all other variables remained significantly worse than the HI. …”
  12. 312

    Table_1_FMT intervention decreases urine 5-HIAA levels: a randomized double-blind controlled study.DOCX by Lihong Wang (14991)

    Published 2024
    “…However, in the placebo group, GSRS, CARS, and SRS scores showed no significant changes, while ABC scores decreased from 72 to 58.75 (p = 0.034). …”
  13. 313
  14. 314
  15. 315
  16. 316

    Data Sheet 2_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf by Mi-Ae Lyu (20413646)

    Published 2025
    “…Ruxolitinib, a JAK/STAT inhibitor, has been shown to improve cutaneous manifestations of SLE. We hypothesize that the addition of ruxolitinib to UCB-Tregs may improve SLE outcomes.…”
  17. 317

    Data Sheet 3_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf by Mi-Ae Lyu (20413646)

    Published 2025
    “…Ruxolitinib, a JAK/STAT inhibitor, has been shown to improve cutaneous manifestations of SLE. We hypothesize that the addition of ruxolitinib to UCB-Tregs may improve SLE outcomes.…”
  18. 318

    Data Sheet 1_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf by Mi-Ae Lyu (20413646)

    Published 2025
    “…Ruxolitinib, a JAK/STAT inhibitor, has been shown to improve cutaneous manifestations of SLE. We hypothesize that the addition of ruxolitinib to UCB-Tregs may improve SLE outcomes.…”
  19. 319
  20. 320

    Data from: <b>Selection and genetic variation in plasticity drive age-related decreases in among-individual behavioural correlations</b> by Chang Seok Han (21814121)

    Published 2025
    “…Our findings indicate that the magnitudes of both the positive among-individual and genetic correlations were maintained across nymph and young adult stages, but significantly decreased with age during adulthood. This decrease was due to both selection and genetic variation in age-related behavioural plasticity. …”